CATAPULT THERAPEUTICS
Catapult Therapeutics is a privately held Dutch biotech company developing CAP-100 – an innovative first-in-class humanized anti-CCR7 antibody. The chemokine receptor CCR7 is over-expressed in many cancers, and high CCR7 expression is associated with poor prognosis and short survival in hematological and solid malignancies. Preclinical studies have shown that the anti-CCR7 antibody can prolong survival and inhibit cancer cell migration in multiple animal models of B-cell and T-cell lymphomas.
CATAPULT THERAPEUTICS
Industry:
Biotechnology
Address:
Lelystad, Flevoland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.catapult-therapeutics.com
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Gubra
Gubra is a privately-held biotech company
Current Employees Featured
Official Site Inspections
http://www.catapult-therapeutics.com
- Host name: web0120.zxcs.nl
- IP address: 185.104.29.84
- Location: Netherlands
- Latitude: 52.3824
- Longitude: 4.8995
- Timezone: Europe/Amsterdam
More informations about "Catapult Therapeutics"
Catapult Therapeutics ~ Targeted Therapy for Cancer
Catapult Therapeutics was established in 2015 as a Dutch privately held joint venture between Spanish and Dutch partners. ... Hoffmann-La Roche, Takeda Pharmaceuticals) and biotech …See details»
Catapult Therapeutics - Crunchbase Company Profile
Catapult Therapeutics is a privately held Dutch biotech company developing CAP-100 – an innovative first-in-class humanized anti-CCR7 antibody. The chemokine receptor CCR7 is over-expressed in many cancers, and high …See details»
Catapult Therapeutics Company Profile 2024: …
Catapult Therapeutics General Information Description. Developer of antibodies designed to inhibit the growth of cancer cells. The company offers antibodies that block tumor cell migration to the lymph nodes together with the potent tumor …See details»
Catapult Therapeutics BV - Drug pipelines, Patents, Clinical trials ...
Explore Catapult Therapeutics BV with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, Drug:CAP-100.See details»
Catapult Therapeutics - LinkedIn
Catapult Therapeutics is a privately held Dutch biotech company developing CAP-100 – an innovative first-in-class humanized anti-CCR7 antibody ...See details»
Catapult Therapeutics - Dulisco
Catapult Therapeutics is a privately held Dutch biotech company developing CAP-100 – an innovative first-in-class humanized anti-CCR7 antibody. The chemokine receptor CCR7 is over …See details»
Catapult Therapeutics welcomes new CEO Dominik Höchli
Apr 15, 2021 Catapult Therapeutics is a privately held Dutch company established in 2015 as a joint venture between Spanish and Dutch venture capital investors. Catapult is founded on the …See details»
Catapult Therapeutics - Products, Competitors, Financials, …
Catapult Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. The company's main product, CAP-100, is an anti-CCR7 …See details»
Catapult Therapeutics receives FDA Clearance of Investigational …
Lelystad, the Netherlands, 8 February 2021 – Catapult Therapeutics, a biopharmaceutical company developing novel cancer treatments, today announced the U.S. Food and Drug …See details»
Catapult Therapeutics - VentureRadar
Bicara Therapeutics USA Private Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to bring together the targeted therapy and tumor …See details»
Catapult Therapeutics - Craft
Catapult Therapeutics is a biotech company developing CAP-100, a humanized anti-CCR7 antibody. It is a humanized IgG1 monoclonal antibody that specifically binds to human CCR7 …See details»
Catapult Receives FDA Clearance of IND for Humanized Anti-CCR7 …
Feb 12, 2021 "The FDA clearance of the IND for CAP-100 represents another important milestone for Catapult Therapeutics, and we look forward to initiating the clinical trial shortly," …See details»
Catapult Therapeutics announces treatment of first patient in …
Lelystad, the Netherlands – November 22, 2021 – Catapult Therapeutics, a clinical-stage biopharmaceutical company developing novel cancer treatments, today announced dosing of …See details»
Catapult Therapy TCR Company Profile 2024: Valuation, Investors ...
Catapult Therapy TCR General Information Description. Provider of cell and gene therapy-related research and development services based in London, United Kingdom. The company …See details»
Catapult Therapeutics receives FDA Clearance of Investigational …
Feb 9, 2021 Catapult Therapeutics, a biopharmaceutical company developing novel cancer treatments, announced the U.S. Food and Drug Administration (FDA) has cleared the …See details»
Advancing acute myeloid leukaemia cell therapy - The Catapult …
A novel cell therapy approach for the treatment of acute myeloid leukaemia developed initially at Imperial College London and then at University College London (UCL) by scientists was …See details»
Catapult Therapeutics announces treatment of first patient in …
On November 22, 2021 Catapult Therapeutics, a clinical-stage biopharmaceutical company developing novel cancer treatments, reported dosing of the first patient in the company’s …See details»
CAP-100 - Drug Targets, Indications, Patents - Synapse - Patsnap
Dec 12, 2024 CAP-100: a CCR7 inhibitors Drug, Initially developed by Catapult Therapeutics BV, Now, its global highest R&D status is Phase 1, Mechanism: CCR7 inhibitors(C-C motif …See details»
Catapult Therapeutics BV (Catapult Therapeutics BV) - 药物管线_专 …
了解Catapult Therapeutics BV (Catapult Therapeutics BV)公司的药物管线，治疗领域，技术平台，以及它的1项临床试，疾病领域:血液及淋巴系统疾病，肿瘤，免疫系统疾病，技术平台:单克 …See details»
CAP 100 - AdisInsight - Springer
08 Feb 2021 Catapult Therapeutics plans a phase Ia/b trial for Chronic lymphocytic leukaemia (Monotherapy, Second line therapy or greater) in USA in the second quarter of 2021 ... You …See details»